Harmon Cyrus's Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Mar 4, 2024
- Accession no.
- 0001415889-24-006322
- Filed
- Mar 4, 2024
- Trade date
- Feb 29, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $310.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harmon CyrusCIK 0001831410 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 29, 2024 | Common Stock | SSaleDisposed | −24,900 | $12.41 | −$309,009 | 846,383 | Direct | |
| Feb 29, 2024 | Common Stock | SSaleDisposed | −100 | $13.00 | −$1,300 | 846,283 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.